SYNGAP1-Related Developmental and Epileptic Encephalopathy — Comprehensive Research Report

A quick orientation before we dive in, because this disease is a bit of a naming hydra: what the clinic now calls SYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1-DEE) is the same entity that OMIM still files under the dusty old label "mental retardation, autosomal dominant 5 (MRD5)." Same gene, same kids, three decades of shifting vocabulary. Think of it like a river that's been renamed by every town it passes through — I'll flag the aliases as we go so the knowledge-base entry can carry them all.

Evidence-hygiene note for the curator (you, Harry): PMIDs I pulled directly from the searches are marked ✓. A handful of foundational mechanism papers I'm citing from background knowledge are marked ⚠︎VERIFY — run just fetch-reference PMID:XXXX on those before any snippet goes into a YAML, per the project's DR-hallucination SOP. I've kept quotes as exact strings from the abstracts I actually fetched.

1. Disease Information

What it is. SYNGAP1-DEE is a monogenic synaptopathy — a disease of the synapse, the little chemical handshake between neurons — caused by having only one working copy of the SYNGAP1 gene (haploinsufficiency). Clinically it's a near-obligate triad: developmental delay/intellectual disability (essentially 100%), generalized epilepsy (~84–92%), and autism/behavioral–sensory abnormalities (~57–68%), layered on early hypotonia (floppiness) and a distinctive, hard-to-treat epilepsy syndrome. Developmental delay almost always shows up first, in the first months to ~2 years of life, and seizures arrive later — a temporal signature that matters diagnostically (Vlaskamp et al. 2019, Neurology, PMID:30541864 ✓).

Key identifiers (from GenCC/OMIM/Orphanet/MalaCards searches): - Gene: SYNGAP1, HGNC:11497, locus 6p21.32 - OMIM disease: #612621 — "Intellectual developmental disorder, autosomal dominant 5; MRD5" - MONDO: MONDO:0012960 (intellectual developmental disorder, autosomal dominant 5); the "SYNGAP1-related developmental and epileptic encephalopathy" concept is also carried by NORD/Orphanet — worth confirming the exact MONDO with runoak since there may be a newer DEE-specific term - Orphanet: ORPHA:544254 - ICD-10: G40.4 (generalized epilepsy) / F79 for the ID axis; ICD-11: LD90.Y (per search) - MeSH: no dedicated descriptor; indexed under Intellectual Disability + Epilepsies, Generalized + SYNGAP1 supplementary concept

Synonyms / alternative names: SYNGAP1-related intellectual disability; SYNGAP1-ID; MRD5; mental retardation, autosomal dominant 5; SYNGAP1 encephalopathy; SYNGAP1-related nonsyndromic ID with epilepsy; SYNGAP1 syndrome (advocacy usage, CureSYNGAP1).

Data provenance. The knowledge base here should draw on aggregated disease-level sources — GeneReviews (NBK537721), Orphanet, and published cohort/registry studies — rather than individual EHR. The two big modern denominators are the SynGAP Research Fund / Ciitizen digital natural-history registry (147 patients, Wiltrout et al. 2024, Epilepsia, PMC12375243 ✓) and the Vlaskamp 2019 international cohort (57 patients, PMID:30541864).

2. Etiology

Primary cause — genetic, monogenic. Heterozygous loss-of-function (LoF) variants in SYNGAP1, or 6p21.32 microdeletions encompassing the gene. The overwhelming majority are de novo (a fresh mutation in the child, not inherited) — this was the founding observation (Hamdan et al. 2009, NEJM 360:599–605, PMID:19196676 ✓; Hamdan et al. 2011, PMID:21237447 ✓). The disease mechanism is dosage — you need two full servings of SynGAP protein and one isn't enough; there's no rescuing spare.

Risk factors. - Genetic: The causal variant IS the risk factor; because it's de novo, classic "susceptibility loci / modifier genes" don't drive occurrence. Advanced parental age is a weak generic contributor to de novo mutation rates (not SYNGAP1-specific). - Environmental / lifestyle / occupational: None established. This is a "bad luck at conception" disorder, not an exposure disorder. No toxin, infection, diet, or occupational link.

Protective factors. No genetic or environmental protective factors are established in humans. Mechanistically interesting caveat from mouse work: the disease is developmental-timing-sensitive, so the "protective" lever is when you restore protein, not any exogenous exposure (see §6/§15).

Gene–environment interactions. Not applicable in the conventional sense. The one real "×environment" axis is seizure triggers: eating and eye-closure provoke reflex seizures in a substantial minority (~25% eating-triggered; Vlaskamp 2019) — an interaction between the genetic substrate and sensory/behavioral state, not toxicology.

3. Phenotypes

The phenotype is a generalized DEE plus a neurodevelopmental disorder. Frequencies below are anchored to the 147-patient registry (Wiltrout 2024 ✓) and the 57-patient Vlaskamp cohort (2019 ✓).

Neurodevelopmental / cognitive - Global developmental delay / intellectual disability — HP:0001263 / HP:0001249. Frequency ~100% ("All patients were diagnosed with global developmental delay (GDD) and/or ID"). Usually moderate–severe, occasionally mild. Onset: infancy; precedes seizures. Course: developmental plateau between ~2 and 5 years, possibly epilepsy-modulated (Kim et al. 2024, AJMG-A, PMID:38563110 ✓). - Absent/impaired speech — HP:0001344 / HP:0000750. Genotype-linked: "83% of individuals with variants in exons 1–4 were able to speak in phrases vs 31% of individuals with variants in exons 5–19" (Wiltrout 2024 ✓). - Autism spectrum disorder / autistic behavior — HP:0000717 / HP:0000729. ~57–68%. - Behavioral problems (HP:0000708) ~68%; anxiety (HP:0000739); aggression/impulsivity.

Epilepsy (the DEE core) — HP:0011097 (generalized), HP:0002133 (status), HP:0002123 (generalized myoclonic) - Generalized epilepsy overall ~84–92%; "Of the 57 patients, 56 had epilepsy: generalized in 55" (Vlaskamp 2019 ✓). - Eyelid myoclonia with absences — HP:0032648 (eyelid myoclonia) / HP:0002121 (absence). ~65% — the signature semiology. - Myoclonic seizures — HP:0032794/HP:0002123. ~34%. - Atypical absences HP:0007270 ~20%; typical absences HP:0011147 ~18%. - Atonic / drop attacks — HP:0010819. ~14%; a novel semiology described as "eyelid myoclonia evolving to a myoclonic-atonic or atonic seizure." - Reflex seizures triggered by eating — ~25%; and by eye closure. - Epilepsy syndromic overlap: myoclonic-atonic epilepsy (Doose), epilepsy with eyelid myoclonia (Jeavons-like), epilepsy with myoclonic absences. - Onset: median ~2 years (Vlaskamp) to 31–34 months (registry), range ~4 months–7 years. Course: often refractory and evolving — up to ~35% show semiology evolution; EEG shifts from occipital → frontal discharges with age (Frontiers/Kim EEG study 2024).

Motor / tone - Hypotonia — HP:0001252 (early, prominent). Ataxia / abnormal gait — HP:0001251 / HP:0001288, ~47%. Unstable/wide-based gait.

Systemic / other - Sleep problems — HP:0002360, ~61%. - Feeding difficulties — HP:0011968, ~47%; oral-motor dysfunction, drooling. - Constipation / GI dysmotility — HP:0002019. - High pain threshold / abnormal pain sensitivity and strabismus (HP:0000486) reported. - Behavioral/sensory abnormalities (sensory-seeking) frequently noted.

Quality-of-life impact. Severe and pervasive: most affected individuals are non- or minimally-verbal, need lifelong supervision, and the combination of refractory seizures + autism + sleep disruption drives heavy caregiver burden. No SYNGAP1-specific EQ-5D/SF-36 dataset exists; QoL is captured qualitatively in registry/advocacy work (Graglia et al. 2025 roadmap, PMID:39807402 ✓).

Genotype–phenotype summary: variants toward the 5′ end (exons 1–6) trend milder for ID/ASD but carry higher refractory-epilepsy risk; SH3-binding-motif variants show lower epilepsy frequency (Hong et al. 2025, Clin Genet; Wiltrout 2024 ✓).

4. Genetic / Molecular Information

Causal gene. SYNGAP1 (synaptic Ras-GTPase-activating protein 1), HGNC:11497, chromosome 6p21.32, ~19 exons, multiple C-terminal isoforms (α1, α2, β, γ). OMIM gene 603384; disease 612621.

Pathogenic variants. - Type/class: predominantly loss-of-function — nonsense, frameshift, canonical splice-site, and a smaller share of missense (often clustering in the C2/GAP catalytic domain). Whole-gene/6p21.32 microdeletions (CNVs) also cause it. LoF-intolerant gene (very high pLI in gnomAD). - ACMG classification: the vast majority are pathogenic/likely pathogenic; truncating de novo variants meet PVS1+PS2. VUS are typically missense. - Allele frequency: essentially absent from population databases (gnomAD) — consistent with a highly penetrant, de novo, LoF disorder. - Origin: germline, de novo in the overwhelming majority; rare inherited cases from a mildly affected or mosaic parent exist (relevant to recurrence counseling). - Functional consequence: haploinsufficiency (loss of function, dosage). Not a classic dominant-negative for truncating alleles, though some C-terminal isoform-specific variants may perturb splice-form balance (Endogenous Syngap1 α splice forms, eLife 2022).

Modifier genes. None validated; residual phenotypic variance is attributed to variant position/isoform impact rather than a mapped modifier.

Epigenetics. No established disease-driving DNA-methylation or histone signature. (A reproducible "episignature" for SYNGAP1 has not been robustly reported the way it has for some other NDD genes — an open question, not an established feature.)

Chromosomal abnormalities. 6p21.32 microdeletions spanning SYNGAP1 are a recognized cause; detectable by chromosomal microarray. Contiguous-gene deletions can add extra features beyond the core phenotype.

Ontology anchors: gene → HGNC:11497; suggest GO/CL/UBERON terms in §6–§7.

5. Environmental Information

Environmental factors: none — no toxin, radiation, pollution, or occupational contribution to disease causation.
Lifestyle factors: none causal. Diet is relevant only therapeutically (ketogenic diet, §12) and as a seizure trigger (eating-induced reflex seizures).
Infectious agents: none — not an infectious or post-infectious disease.

This section is genuinely not applicable as an etiologic axis; SYNGAP1-DEE is purely genetic.

6. Mechanism / Pathophysiology

Here's where the biology gets gorgeous. Picture the excitatory synapse's postsynaptic density (PSD) as a crowded loading dock. SynGAP is one of the most abundant proteins on that dock — a Ras/Rap GTPase-activating protein tethered to the NMDA-receptor complex via PSD-95. Its day job is to keep the Ras→ERK/MAPK and Rap signaling switches turned off until a legitimate calcium signal (through the NMDA receptor + CaMKII) says "go." SynGAP is thus a brake on synaptic strengthening (Frontiers "SYNGAP1: Mind the Gap," PMID:26912996 ✓).

The causal chain (upstream → downstream):

Trigger — SynGAP haploinsufficiency. ~50% less SynGAP protein at the PSD.
Dysregulated small-GTPase signaling. Loss of GAP activity → constitutively elevated Ras-GTP → hyperactive ERK/MAPK, plus disturbed Rap signaling. The brake is half-off. (GO:0032312 regulation of ARF/Ras GTPase activity; GO:0007265 Ras signal transduction; GO:0000186 activation of MAPKK activity.)
Aberrant AMPA-receptor trafficking. Excess Ras/ERK drives premature insertion of AMPA receptors into the postsynaptic membrane, increasing excitatory synaptic strength too early. (GO:0032281 AMPA glutamate receptor complex; GO:0098976 excitatory chemical synaptic transmission.)
Precocious dendritic-spine maturation. Spines "grow up too fast," shortening the critical window of plasticity — the developmental period when circuits are supposed to stay malleable (Clement et al. 2012, Cell 151:709–723 ⚠︎VERIFY PMID:23141539; critical-period paper, PMC4326604). (GO:0060997 dendritic spine morphogenesis; GO:0050803 regulation of synapse structure/activity.)
Circuit-level E/I imbalance. "Early hard-wiring" of cortical and thalamocortical circuits → excitation/inhibition imbalance, abnormal cortical oscillations, and impaired plasticity → the substrate for both cognitive impairment and generalized seizures (synaptic-neoteny study, Neuron 2024).
Clinical manifestation. ID + generalized epilepsy + autistic/behavioral features.

This maps cleanly onto your existing epilepsy_excitation_inhibition_imbalance module — the conserved chain "ion-channel/synaptic dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures." SYNGAP1-DEE is a near-textbook synaptic (rather than ion-channel) conformer of epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance. Worth a conforms_to edge.

Protein dysfunction: loss of a PSD scaffold-associated enzyme → downstream signaling deregulation (not aggregation/misfolding). UniProt Q96PV0 (SYNGAP1_HUMAN).

Cellular processes / cell types: the disorder is intrinsic to excitatory glutamatergic cortical/hippocampal pyramidal neurons (CL:0000598 pyramidal neuron; CL:0000679 glutamatergic neuron; CL:0000617/CL:0000540 neuron), with interneuron-circuit consequences. Subcellular: the postsynaptic density of the dendritic spine (GO:0014069 postsynaptic density; GO:0043197 dendritic spine).

Metabolic / immune / fibrosis / oxidative: none primary — this is not a metabolic, autoimmune, or degenerative disease.

Molecular profiling / advanced tech: human xenotransplanted cortical neuron and iPSC models show disrupted "synaptic neoteny" (the human-specific slow synapse maturation), tying SynGAP loss to accelerated human-neuron maturation (Neuron 2024). Mouse cortical CRISPR/functional-genomics and re-expression studies underpin the reversibility work (§15). No disease-defining metabolomic/proteomic biomarker panel exists yet.

7. Anatomical Structures Affected

Organ / system: central nervous system (UBERON:0001017), specifically cerebral cortex (UBERON:0000956) and hippocampus (UBERON:0002421); thalamocortical circuitry implicated. Body system: nervous system (predominant); secondary GI dysmotility (enteric nervous system) and no primary cardiac/renal/hepatic involvement.
Tissue / cell: gray-matter neural tissue; excitatory glutamatergic pyramidal neurons (CL:0000598) are the primary affected population; downstream inhibitory-interneuron circuit dysfunction.
Subcellular: postsynaptic density (GO:0014069) of dendritic spines (GO:0043197) on excitatory synapses (GO:0060076); the NMDA-receptor/PSD-95 signaling complex.
Localization / laterality: bilateral, diffuse/generalized cortical involvement (consistent with generalized epilepsy and global ID); brain MRI is usually normal or nonspecific — this is a functional/microstructural, not gross-structural, disorder.

8. Temporal Development

Onset: congenital/infantile for the neurodevelopmental axis — hypotonia and developmental delay in the first months to ~2 years, before seizures. Epilepsy onset median ~2 years (range ~4 months–7 years).
Pattern: chronic, largely static-to-plateauing developmental course rather than frank neurodegeneration; a notable plateau/relative regression window at ~2–5 years (Kim 2024 ✓).
Epilepsy course: frequently drug-resistant and evolving — semiology and EEG change over childhood (occipital→frontal discharge migration; eyelid myoclonia → myoclonic → atonic evolution in ~35%).
Remission: seizures may improve in some by adolescence/adulthood but ID and autism persist lifelong; spontaneous remission of the disorder does not occur.
Critical period: the animal data make this the therapeutically pivotal concept — an embryonic/early-postnatal developmental window during which circuit assembly is derailed, with implications for the timing of any disease-modifying therapy (§15).

9. Inheritance and Population

Inheritance. Autosomal dominant, HP:0000006; nearly always de novo. Penetrance essentially complete for the LoF variants; expressivity variable (severity tracks variant position/isoform). No anticipation (not a repeat-expansion disorder). Germline/somatic mosaicism in a parent is a real, if uncommon, recurrence mechanism → warrants parental testing and counseling. No founder effects, no consanguinity role, no carrier-frequency concept (it's not a recessive/carrier disease).

Epidemiology. Prevalence figures diverge sharply by source and this is worth flagging in the KB: - Orphanet lists <1/1,000,000 as a documented point prevalence — almost certainly an underestimate (SYNGAP1 is widely regarded as under-diagnosed, CureSYNGAP1). - Yield-based estimates are much higher: ~1% of epileptic encephalopathy cohorts and ~0.75% of unexplained ID cohorts carry pathogenic SYNGAP1 variants (GeneReviews NBK537721; Vlaskamp 2019 ✓). Some reviews put the population incidence at 1–4/10,000, i.e. ~0.5–4% of ID, making it one of the more common single-gene causes of ID-with-epilepsy. - Curation guidance: record the coarse band honestly — the true population prevalence is genuinely uncertain; the diagnostic yield numbers (~1% of DEE, ~0.75% of ID) are the more defensible, better-sourced claims. In your Prevalence schema I'd use measure_type: POINT_PREVALENCE, prevalence_class for the Orphanet band, but lean on the yield statistics in notes with their cohort context.

Demographics. No ethnic predilection; global distribution (de novo). Sex ratio ~1:1 (50% male in both the 147- and 57-patient cohorts). Age distribution: pediatric-diagnosed, lifelong condition; adult cases increasingly recognized via reanalysis (adult WES "cold case," PMC10617251).

10. Diagnostics

The diagnosis is genetic. There is no biochemical or imaging test that makes it — those support and exclude.

Genetic testing (definitive): - First-line: broad genomic testing — exome (WES) or genome (WGS), or a DEE/ID multigene panel that includes SYNGAP1. High-yield in the "developmental delay → later generalized epilepsy" phenotype. - Chromosomal microarray (CMA): catches 6p21.32 microdeletions that sequencing panels can miss. - Single-gene testing / targeted variant analysis: for family cascade or confirming a specific variant. - Parental testing: to establish de novo status and screen for mosaicism (recurrence risk). - Karyotype/FISH/mtDNA/repeat-expansion testing: low yield / not indicated for the typical presentation.

Supportive / phenotyping tests: - EEG (the key functional test): generalized (poly)spike-wave, often with eyelid-myoclonia-associated discharges, photosensitivity, eating/eye-closure-triggered discharges; occipital→frontal shift with age. EEG is central to characterizing the epilepsy but is not specific. - Brain MRI: usually normal/nonspecific — its main value is ruling out structural mimics. - Developmental / neuropsychological assessment, autism evaluation (ADOS/ADI-R), sleep evaluation. - No validated blood/CSF biomarker exists.

Clinical criteria & differential. No formal consensus criteria; diagnosis rests on genotype + compatible phenotype. Differential diagnosis (the "generalized DEE with myoclonic/absence/atonic seizures + ID" neighborhood): Dravet syndrome (SCN1A), Doose/myoclonic-atonic epilepsy, Jeavons syndrome (eyelid myoclonia with absences), Lennox-Gastaut syndrome, Angelman syndrome (UBE3A), STXBP1-, SLC6A1-, GABA-pathway DEEs, and KANSL1/other ID-with-epilepsy genes. Distinguishing feature: developmental delay clearly preceding seizure onset, plus the eyelid-myoclonia/eating-triggered semiology.

Screening. Not on newborn-screening panels; no carrier screening (de novo dominant). Ascertainment is via diagnostic genomic testing in ID/DEE, and increasingly via exome/genome reanalysis of previously undiagnosed patients — a real-world driver of the "under-diagnosed" story.

11. Outcome / Prognosis

Survival / mortality: Life expectancy is generally not markedly shortened, and it is not a primarily lethal disorder; however, like other refractory DEEs it carries an elevated risk of SUDEP (sudden unexpected death in epilepsy) and seizure/status-related and aspiration-related morbidity. No robust disease-specific mortality rate is published.
Morbidity / function: high lifelong disability — most individuals are non-/minimally verbal, dependent for daily activities, and require lifelong support. Autism, sleep disruption, and behavioral challenges compound the ID.
Disease course / complications: refractory epilepsy, injury from atonic drop attacks, feeding/aspiration issues, constipation, sleep disorder, behavioral crises.
Recovery potential: the ID/autism axis is stable and permanent with current care; seizures are often refractory but may attenuate over time in some. No spontaneous recovery.
Prognostic factors: variant position/isoform and epilepsy severity/refractoriness are the main prognostic levers (e.g., 5′/exon-1–4 variants → better language outcomes; refractory epilepsy → worse developmental trajectory). No validated prognostic biomarker beyond genotype.
QoL measures: no SYNGAP1-specific instrument; generic pediatric-NDD and caregiver-burden tools are used in registry/advocacy contexts.

12. Treatment

Bottom line: no disease-modifying therapy is approved yet — care is symptomatic — but the precision-medicine pipeline is unusually active (Graglia et al. 2025 roadmap, PMID:39807402 ✓).

Antiseizure medications (mainstay; MAXO:0000058 pharmacotherapy / MAXO:0000630 pharmacotherapy): - Broad-spectrum ASMs favored for generalized/myoclonic seizures: valproate, lamotrigine, levetiracetam, ethosuximide (for absences), clobazam, and cannabidiol (Epidiolex) — the latter with reported benefit in SYNGAP1-associated refractory/myoclonic-atonic epilepsy (CBD in MAE, Epileptic Disorders 2025). - Caution: as with other generalized epilepsies, sodium-channel blockers (e.g., carbamazepine/phenytoin) can worsen myoclonic/absence seizures. - Ketogenic diet (MAXO:0001056 / dietary intervention MAXO:0000088) — used in refractory cases with anecdotal benefit.

Supportive / rehabilitative (large share of real-world management): - Speech-language therapy, occupational therapy, physical therapy (MAXO:0000011 physical therapy; MAXO:0000020-class rehabilitation), AAC (augmentative communication) devices. - Behavioral/ASD interventions, sleep management (melatonin), feeding/GI management, genetic counseling (MAXO:0000079).

Investigational / disease-modifying pipeline (the exciting part): - Antisense oligonucleotides (ASOs): the leading modality. CAMP4 Therapeutics' CMP-SYNGAP-01 — an intrathecal ASO that upregulates SYNGAP1 expression (a "regulatory RNA"/upregulation approach rather than knockdown) — entered GLP toxicology in Oct 2025, with a Phase 1/2 first-in-human start targeted for 2H 2026 (CAMP4 announcement). Multiple companies + academic groups have ASO and AAV programs in pipelines (roadmap PMID:39807402 ✓). - AAV gene therapy: preclinical AAV delivery of full-length SYNGAP1 rescued epileptic and behavioral phenotypes in mice (Molecular Therapy 2025) — proof-of-concept for gene supplementation. - Discontinued for the class: soticlestat (TAK-935), a cholesterol-24-hydroxylase inhibitor trialed across DEEs, was discontinued by Takeda in 2025 after Phase 3 misses in Dravet/LGS (Takeda statement) — it was never SYNGAP1-specific. - Other explored approaches: taurine supplementation and ketogenic diet (anecdotal); ERK/MAPK-pathway modulation is a rational target given the mechanism but not clinically validated.

Pharmacogenomics / personalized medicine: the whole point of the ASO/AAV work is genotype-directed dosage restoration; ASO eligibility is being formally assessed for SYNGAP1 among infantile genetic epilepsies (medRxiv 2025).

Treatment strategy: individualized ASM selection for generalized/myoclonic semiology + aggressive developmental/behavioral support; enrollment in the SYNGAP1/Brain Gene Registry and natural-history studies to be trial-ready (Brain Gene Registry, PMID:40282364 ✓).

13. Prevention

Primary prevention: not possible — de novo dominant mutation; no modifiable exposure. Only reproductive options apply for a family with an identified proband: prenatal diagnosis or preimplantation genetic testing (PGT-M) in the rare inherited/mosaic-parent scenario, and recurrence-risk counseling (empirically low but non-zero due to possible parental germline mosaicism).
Secondary prevention (early detection → early intervention): the actionable lever. Early genomic diagnosis (broad WES/WGS in ID/DEE, plus exome reanalysis) enables early developmental therapy and trial-readiness — and, if disease-modifying therapy arrives, the developmental critical period makes early treatment potentially decisive.
Tertiary prevention (complication reduction): seizure control to limit injury/SUDEP, aspiration/nutrition management, sleep and behavioral support, physical/OT to preserve function.
Immunization / public-health / environmental measures: not applicable (not infectious/environmental).
Genetic counseling (MAXO:0000079) is the central preventive-medicine service: de novo status confirmation, mosaicism screening, and family-planning guidance.

14. Other Species / Natural Disease

Taxonomy of the ortholog: SYNGAP1 is deeply conserved across vertebrates — human NCBITaxon:9606, mouse Syngap1 (NCBITaxon:10090, MGI), rat (NCBITaxon:10116), zebrafish (NCBITaxon:7955, ZFIN).
Naturally occurring disease in animals: none catalogued — there is no spontaneous companion-animal or livestock SYNGAP1 disease in OMIA; all animal disease is engineered (see §15). So this is genuinely not applicable as a "natural disease of other species."
Comparative biology / evolutionary conservation: the NMDAR–SynGAP–Ras/ERK–AMPAR synaptic module is highly conserved, which is why rodent models translate mechanistically. A striking human-specific twist: "synaptic neoteny" (protracted human synapse maturation) is disrupted by SynGAP loss in xenotransplanted human neurons — a conservation-with-a-human-difference story (Neuron 2024).
Zoonotic potential / cross-species transmission: not applicable (genetic, non-transmissible).

15. Model Organisms

The model story is the crown jewel here, because it delivered the field's central hope: the disorder may be at least partly reversible even after development.

Mouse (Syngap1^+/− heterozygous knockout) — the workhorse (MGI). Recapitulates cognitive deficits, autistic-like behaviors, and epilepsy/interictal spiking (comprehensive behavioral analysis, PMC7292322). Homozygous null is embryonic-lethal — consistent with dosage-critical function.
Critical-period / developmental-timing models: Syngap1 haploinsufficiency "damages a postnatal critical period of pyramidal cell structural maturation linked to cortical circuit assembly" (PMC4326604). Conditional/temporal genetic-rescue experiments show full protection when the gene is restored in cortical progenitors mid-to-late embryonically, but limited benefit from CNS-wide reversal begun in adulthood — establishing a developmental window.
Adult-reversal models (the therapeutic-optimism papers): "Re-expression of SynGAP protein in adulthood improves translatable measures of brain function and behavior" (Creson/Rumbaugh et al., eLife 2019) — adult restoration improved memory measures and eliminated sleep-worsened interictal events. So: development sets the ceiling, but adult intervention still moves meaningful endpoints — the biological rationale for ASO/gene therapy in already-diagnosed children and adults.
Isoform models: endogenous α-splice-form manipulation shows specific isoforms promote cognition and seizure protection (eLife 2022) — relevant to designing expression-restoring therapeutics.
Gene-therapy proof-of-concept: AAV full-length SYNGAP1 rescued epileptic and behavioral phenotypes in the mouse model (Molecular Therapy 2025).
Human cellular models: iPSC-derived neurons, cortical organoids, and xenotransplanted human cortical neurons — reveal disrupted synaptic neoteny/maturation (Neuron 2024); ideal for evidence_source: IN_VITRO. Other systems: rat, zebrafish, and Drosophila orthologs exist for pathway work.
Model limitations: mouse heterozygotes under-model the full human seizure severity (interictal spikes ± occasional seizures rather than the florid human eyelid-myoclonia/absence syndrome); and the human-specific neoteny biology can't be captured in rodent neurons — a genuine HUMAN_MODEL_MISMATCH candidate for your KB (evidence exists in models, but translational fidelity of the seizure phenotype and the human-maturation timeline is the open question).

Curation notes for the dismech entry

Module conformance: strong conforms_to: epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance — SYNGAP1-DEE is a clean synaptic (non-channel) conformer. The mechanistic chain in §6 gives you the trigger→consequence nodes.
HUMAN_MODEL_MISMATCH discussion: the mouse-vs-human seizure-severity gap and the human synaptic-neoteny biology are worth a kind: HUMAN_MODEL_MISMATCH discussion, not a generic knowledge gap — evidence exists in models, fidelity is the question.
Prevalence honesty: curate the Orphanet <1/1,000,000 band but foreground the ~1% of DEE / ~0.75% of ID yield statistics with cohort context in notes; note explicit under-diagnosis.
Genotype–phenotype: the exon-1–4 vs exon-5–19 language split and the 5′/refractory-epilepsy trade-off are quotable, well-sourced, and belong in genetic/subtype notes.
⚠︎VERIFY before snippeting: re-fetch PMIDs I cited from background memory (Clement 2012 Cell ~PMID:23141539; eLife 46752/75707; PMC4326604 — confirm authors/year) with just fetch-reference and confirm exact abstract substrings. The ✓-marked PMIDs (19196676, 21237447, 30541864, 38563110, 39807402, 40282364) came straight from the searches and the two fetched abstracts (PMC6340340, PMC12375243) gave verbatim quotes you can lift directly.

Sources: - Vlaskamp et al. 2019, Neurology — SYNGAP1 encephalopathy: a distinctive generalized DEE (PMID:30541864) - Wiltrout et al. 2024, Epilepsia — Comprehensive phenotypes of SYNGAP1-related disorder (147 patients) - Kim et al. 2024, Am J Med Genet A — genotype/phenotype & longitudinal insights (PMID:38563110) - Hamdan et al. 2009, NEJM — Mutations in SYNGAP1 in nonsyndromic MR (PMID:19196676) - Hamdan et al. 2011 — De novo SYNGAP1 mutations in nonsyndromic ID and autism (PMID:21237447) - GeneReviews — SYNGAP1-Related Intellectual Disability (NBK537721) - Orphanet — SYNGAP1-related DEE (ORPHA:544254) - OMIM #612621 — MRD5 - Frontiers — "SYNGAP1: Mind the Gap" (PMID:26912996) - Clement et al. 2012, Cell — pathogenic SYNGAP1 mutations & dendritic-spine maturation - Creson/Rumbaugh et al. 2019, eLife — adult re-expression of SynGAP - Critical-period damage paper, PMC4326604 - Endogenous Syngap1 α splice forms, eLife 2022 - AAV full-length SYNGAP1 rescue, Molecular Therapy 2025 - SYNGAP1 deficiency disrupts synaptic neoteny, Neuron 2024 - Graglia et al. 2025 — SynGAP Research Fund therapeutics roadmap (PMID:39807402) - SYNGAP1 Syndrome and the Brain Gene Registry, 2025 (PMID:40282364) - CAMP4 CMP-SYNGAP-01 GLP toxicology announcement, Oct 2025 - Takeda soticlestat (TAK-935) discontinuation, 2025 - Comprehensive behavioral analysis of heterozygous Syngap1 KO mice, PMC7292322 - Hong et al. 2025, Clinical Genetics — genotype–phenotype correlations in MRD5